Paper3966974
Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
Lee FY and 1 other. Br J Cancer, 1985. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU. Papers, record 3966974. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3966974
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fibrosarcoma | Major topic |
| Lomustine | Major topic |
| Misonidazole | Major topic |
| Nitroimidazoles | Major topic |
| Administration, Oral | |
| Animals | |
| Drug Interactions | |
| Injections, Intraperitoneal | |
| Lethal Dose 50 | |
| Male | |
| Mice | |
| Mice, Inbred C3H |
Source PubMed
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7459221 | In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. | Br J Cancer | 1980 | https://conductscience.org/library/papers/7459221 | PubMed |
| 2 | 5527023 | Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. | Cancer Chemother Rep | 1970 | https://conductscience.org/library/papers/5527023 | PubMed |
| 3 | 6480457 | A phase I study of the combination of benznidazole and CCNU in man. | Int J Radiat Oncol Biol Phys | 1984 | https://conductscience.org/library/papers/6480457 | PubMed |
| 4 | 145865 | Comparison of the properties of metabolites of CCNU. | Biochem Pharmacol | 1977 | https://conductscience.org/library/papers/145865 | PubMed |
| 5 | 528273 | The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin. | Int J Radiat Oncol Biol Phys | 1979 | https://conductscience.org/library/papers/528273 | PubMed |
| 6 | 7225287 | In vivo combination of misonidazole and the chemotherapeutic agent CCNU. | Br J Cancer | 1981 | https://conductscience.org/library/papers/7225287 | PubMed |
| 7 | 6895696 | A comparison of adriamycin and mAMSA in vitro: cell lethality and SCE studies. | Br J Cancer | 1981 | https://conductscience.org/library/papers/6895696 | PubMed |
| 8 | 6460517 | Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers. | Br J Cancer | 1982 | https://conductscience.org/library/papers/6460517 | PubMed |
| 9 | 7073947 | Growth delay in small EMT6 spheroids induced by cytotoxic drugs and its modification by misonidazole pretreatment under hypoxic conditions. | Br J Cancer | 1982 | https://conductscience.org/library/papers/7073947 | PubMed |
| 10 | 7081141 | Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts. | Am J Clin Oncol | 1982 | https://conductscience.org/library/papers/7081141 | PubMed |
| 11 | 7201845 | Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain. | Br J Cancer | 1982 | https://conductscience.org/library/papers/7201845 | PubMed |
| 12 | 7107378 | Enhancement of chemotherapy agents. | Int J Radiat Oncol Biol Phys | 1982 | https://conductscience.org/library/papers/7107378 | PubMed |
| 13 | 7150475 | Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU. | Br J Cancer | 1982 | https://conductscience.org/library/papers/7150475 | PubMed |
| 14 | 6838633 | Drug metabolism and chemosensitization. Nitroimidazoles as inhibitors of drug metabolism. | Biochem Pharmacol | 1983 | https://conductscience.org/library/papers/6838633 | PubMed |
| 15 | 6849803 | Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6849803 | PubMed |
| 16 | 6883348 | Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole. | Cancer Res | 1983 | https://conductscience.org/library/papers/6883348 | PubMed |
| 17 | 6615699 | The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse. | Br J Cancer | 1983 | https://conductscience.org/library/papers/6615699 | PubMed |
| 18 | 6722006 | Misonidazole and CCNU: further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain. | Br J Cancer | 1984 | https://conductscience.org/library/papers/6722006 | PubMed |
| 19 | 6384159 | Modification of chemotherapy by nitroimidazoles. | Int J Radiat Oncol Biol Phys | 1984 | https://conductscience.org/library/papers/6384159 | PubMed |
| 20 | 7460192 | Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/7460192 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 3948306 | Pharmacokinetics in experimental and clinical chemotherapy. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/3948306 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3966974
GET https://conductscience.org/api/papers/v1/3966974/authors